Jana Fuchs LPC

Recommended Articles

• Apgar Score: the five signs evaluated

  Apgar Score: the five signsRight after birth, the health of a newborn baby is evaluated using the Apgar score, in which five factors are measured on a scale of zero to two. These scores are then added to give the final value which ranges from zero to ten. Thus, the overall health of the newborn baby...

• Understanding the Different Types of Multiple Sclerosis

  Since MS does not progress in the same manner, professionals have divided the disease into four phenotypes based on the manner in which the disease progresses. The four types of multiple sclerosis are Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Primary Progressive Multiple...

• What Causes Ingrown Hairs?

  An ingrown hair is the bump that refuses to go away, the reddish rash that becomes an eyesore, and the dull pain sparked by normal contact. If there’s anything capable of making life a living hell, it’s an ingrown hair.Basically, normal hair grows out of the follicle with only its root firmly...

• How to Help Your Child with ASD Socially Excel at School

  Just because social challenges like communication impairment are one of the indications of autism, it does not imply that they are normal for children on the spectrum. Considering that, some parents experience challenges getting their kids to do such simple things as putting on winter clothes,...

• Healing and Recovery After Breast Cancer Diagnosis

  What was (or would be) the first thoughts and emotions you would experience if a doctor ever looked you square in your eyes and said, “I’m sorry but you have breast cancer”?For Mary, diagnosed when she was in her late 30s, her first thought was “no I don’t,” and of course her first words...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...